Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer

Epigenetics

Volumn 7, Issue 9, 2012, Pages 1037-1045

  Olkhov Mitsel, Ekaterina ^a,b   Van der Kwast, Theodorus ^b,c   Kron, Ken J ^a,b   Ozcelik, Hilmi ^a   Briollais, Laurent ^a   Massey, Christine ^d   Recker, Franz ^e   Kwiatkowski, Maciej ^e   Fleshner, Neil E ^f   Diamandis, Eleftherios P ^a,b,c   Zlotta, Alexandre R ^a,d   Bapat, Bharati ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e CANTONAL HOSPITAL AARAU   (Switzerland)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomarkers; Epigenetics; Kallikrein related peptidases; Prostate cancer; Quantitative DNA methylation analysis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; KALLIKREIN 10; KALLIKREIN 6; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

EID: 84866090183     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.21524     Document Type: Article

References (48)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-36; http://dx.doi.org/10.3322/caac.20121.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; http://dx.doi.org/10.3322/caac.20107.
3. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350:2239-46; http://dx.doi.org/10.1056/NEJMoa031918.
4. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating character-istics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294:66-70; http://dx.doi.org/10.1001/jama.294.1.66.
5. Gleason DF. Classification of prostatic carcino-mas. Cancer Chemother Rep 1966; 50:125-8;
6. Sved PD, Gomez P, Manoharan M, Kim SS, Soloway MS. Limitations of biopsy Gleason grade: implica-tions for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol 2004; 172:98-102; http://dx.doi.org/10.1097/01.ju.0000132135.18093.d6.
7. Adams RL, Burdon RH. DNA methylation in eukaryotes. CRC Crit Rev Biochem 1982; 13:349-84; http://dx.doi.org/10.3109/10409238209108714.
8. Laird PW, Jaenisch R. DNA methylation and can-cer. Hum Mol Genet 1994; 3(Spec No):1487-95;
9. Kron KJ, Liu L, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, et al. DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest 2010; 90:1060-7; http://dx.doi.org/10.1038/labinvest.2010.57.
10. Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, et al. Association of tissue pro-moter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 2011; 129:2454-62; http://dx.doi.org/10.1002/ijc.25908.
11. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004; 91:540-52; http://dx.doi.org/10.1002/jcb.10740.
12. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, et al. DNA methylation of the PITX2 gene promoter region is a strong independent prog-nostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009; 181:1678-85; http://dx.doi.org/10.1016/j.juro.2008.11.120.
13. Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, et al. New nomenclature for the human tissue kallikrein gene family. Clin Chem 2000; 46:1855-8;
14. Lundwall A, Clauss A, Olsson AY. Evolution of kalli-krein-related peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibi-tors. Biol Chem 2006; 387:243-9; http://dx.doi.org/10.1515/BC.2006.032.
15. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010; 391:505-11; http://dx.doi.org/10.1515/bc.2010.056.
16. Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4:876-90; http://dx.doi.org/10.1038/nrc1474.
17. Pampalakis G, Diamandis EP, Sotiropoulou G. The epigenetic basis for the aberrant expression of kal-likreins in human cancers. Biol Chem 2006; 387:795-9; http://dx.doi.org/10.1515/BC.2006.100.
18. Li B, Goyal J, Dhar S, Dimri G, Evron E, Sukumar S, et al. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res 2001; 61:8014-21;
19. Zhang Y, Song H, Miao Y, Wang R, Chen L. Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci 2010; 101:934-40; http://dx.doi.org/10.1111/j.1349-7006.2009.01486.x.
20. Huang W, Zhong J, Wu LY, Yu LF, Tian XL, Zhang YF, et al. Downregulation and CpG island hypermeth-ylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett 2007; 251:78-85; http://dx.doi.org/10.1016/j.can-let.2006.11.006.
21. Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hyper-methylation in breast, ovarian and prostate cancers. Tumour Biol 2005; 26:324-36; http://dx.doi.org/10.1159/000089290.
22. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, et al. Discovery of novel hyper-methylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 2009; 4:e4830; http://dx.doi.org/10.1371/journal.pone.0004830.
23. Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mes-enchymal transition. Cancer Res 2009; 69:3779-87; http://dx.doi.org/10.1158/0008-5472.CAN-08-1976.
24. Pampalakis G, Sotiropoulou G. Multiple mechanisms underlie the aberrant expression of the human kal-likrein 6 gene in breast cancer. Biol Chem 2006; 387:773-82; http://dx.doi.org/10.1515/BC.2006.097.
25. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycyt-idine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21:5483-95; http://dx.doi.org/10.1038/sj.onc.1205699.
26. Epstein JI, Carmichael M, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol 1993; 149:1040-5;
27. Veltri RW, Miller MC, Partin AW, Coffey DS, Epstein JI. Ability to predict biochemical progression using Gleason score and a computer-generated quantita-tive nuclear grade derived from cancer cell nuclei. Urology 1996; 48:685-91; http://dx.doi.org/10.1016/S0090-4295(96)00370-6.
28. Lu CY, Hsieh SY, Lu YJ, Wu CS, Chen LC, Lo SJ, et al. Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepa-tocellular carcinoma. Genes Chromosomes Cancer 2009; 48:1057-68; http://dx.doi.org/10.1002/gcc.20708.
29. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Barrios M, Andreu EJ, et al. The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 2004; 18:362-5; http://dx.doi.org/10.1038/sj.leu.2403223.
30. Jones PA. The DNA methylation paradox. Trends Genet 1999; 15:34-7; http://dx.doi.org/10.1016/S0168-9525(98)01636-9.
31. Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis 2003; 6:223-7; http://dx.doi.org/10.1038/sj.pcan.4500674.
32. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1998; 58:4782-6;
33. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, et al. DNA methyla-tion profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 2011; 21:1017-27; http://dx.doi.org/10.1101/gr.119487.110.
34. van der Heul-Nieuwenhuijsen L, Hendriksen PJ, van der Kwast TH, Jenster G. Gene expression profiling of the human prostate zones. BJU Int 2006; 98:886-97; http://dx.doi.org/10.1111/j.1464-410X.2006.06427.x.
35. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10:8472-8; http://dx.doi.org/10.1158/1078-0432.CCR-04-0894.
36. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, et al. Age-related DNA meth-ylation changes in normal human prostate tissues. Clin Cancer Res 2007; 13:3796-802; http://dx.doi.org/10.1158/1078-0432.CCR-07-0085.
37. Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate. Prostate 2009; 69:1470-9; http://dx.doi.org/10.1002/pros.20983.
38. Slaughter DP, Southwick HW, Smejkal W. Field can-cerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963-8; http://dx.doi.org/10.1002/1097-0142(195309)6:5963::AID-CNCR28200605153.0.CO;2-Q.
39. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, et al. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006; 98:255-61; http://dx.doi.org/10.1093/jnci/djj051.
40. Yousef GM, White NM, Michael IP, Cho JC, Robb JD, Kurlender L, et al. Identification of new splice variants and differential expression of the human kallikrein 10 gene, a candidate cancer biomarker. Tumour Biol 2005; 26:227-35; http://dx.doi.org/10.1159/000087377.
41. Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, Akre O, et al. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 2009; 27:3161-8;; http://dx.doi.org/10.1200/JCO.2008.18.2485.
42. Phé V, Cussenot O, Rouprêt M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010; 105:1364-70; http://dx.doi.org/10.1111/j.1464-410X.2009.09167.x.
43. Ehrich M, Böcker S, van den Boom D. Multiplexed discovery of sequence polymorphisms using base-specific cleavage and MALDI-TOF MS. Nucleic Acids Res 2005; 33:e38; http://dx.doi.org/10.1093/nar/gni038.
44. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. MethyLight: a high-through-put assay to measure DNA methylation. Nucleic Acids Res 2000; 28:E32; http://dx.doi.org/10.1093/nar/28.8.e32.
45. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005; 33:6823-36; http://dx.doi.org/10.1093/nar/gki987.
46. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, et al. Promoter hyper-methylation as an independent prognostic factor for relapse in patients with prostate cancer following radi-cal prostatectomy. Clin Cancer Res 2005; 11:8321-5; http://dx.doi.org/10.1158/1078-0432.CCR-05-1183.
47. Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, et al. High promoter meth-ylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007; 13:6122-9; http://dx.doi.org/10.1158/1078-0432.CCR-07-1042.
48. Rothman KJ. No adjustments are need-ed for multiple comparisons. Epidemiology 1990; 1:43-6; http://dx.doi.org/10.1097/00001648-199001000-00010.